Lazard上市基礎設施主動型ETF GLIX 深 滬
交易中 10-08 10:51:49 美东时间
25.39
-0.040
-0.16%
華盛通- 最 高25.39
- 今 開25.36
- 成交量 1077股
- 最 低 25.36
- 昨 收 25.43
- 總市值 4442.44万
- 52周最高 29.23
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 24.7399
- 委 比 0.00%
- 總股本 174.97万
- 歷史最高 30.47
- 量 比 0.40
- 振 幅 0.12%
- 歷史最低 24.7399
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15
The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors. Presentation Details: Title:...
今天 19:05
BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
05-19 19:04
BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
04-28 19:13
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
An update from Bioline RX Ltd Sponsored ADR ( ($BLRX) ) is now available. BioLi...
03-26 19:28
BioLineRx Launches First Human Trial For Brain Cancer Drug
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
03-26 19:17
